Provided by Tiger Trade Technology Pte. Ltd.

Tenax Therapeutics

14.90
-0.0700-0.47%
Post-market: 12.49-2.4105-16.18%19:53 EDT
Volume:360.69K
Turnover:5.41M
Market Cap:256.24M
PE:-11.11
High:15.25
Open:14.99
Low:14.39
Close:14.97
52wk High:18.38
52wk Low:4.63
Shares:17.20M
Float Shares:4.51M
Volume Ratio:1.16
T/O Rate:8.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3412
EPS(LYR):-1.3412
ROE:-55.64%
ROA:-35.08%
PB:2.64
PE(LYR):-11.11

Loading ...

Tenax Therapeutics Is Maintained at Buy by Guggenheim

Dow Jones
·
Dec 17, 2025

Tenax Therapeutics Chief Medical Officer Stuart Rich Reports Acquisition of Common Shares

Reuters
·
Dec 11, 2025

Tenax Therapeutics Chief Medical Officer Stuart Rich Reports Acquisition of Common Shares

Reuters
·
Dec 06, 2025

Tenax Therapeutics Executives to Present at Major Healthcare Investor Conferences

Reuters
·
Nov 25, 2025

CEO Makes Bold Move with Major Stock Purchase in Tenax Therapeutics!

TIPRANKS
·
Nov 21, 2025

Director’s Bold Move: A Significant Investment in Tenax Therapeutics!

TIPRANKS
·
Nov 20, 2025

Tenax Therapeutics Director June Sherie Almenoff Reports Acquisition of Common Shares

Reuters
·
Nov 20, 2025

Tenax Therapeutics Q3 Net Income USD -15.804 Million

Reuters
·
Nov 20, 2025

Tenax Therapeutics Inc : Leerink Partners Raises Target Price to $26 From $20

THOMSON REUTERS
·
Nov 14, 2025

Tenax Therapeutics to hold a conference call

TIPRANKS
·
Nov 13, 2025

Tenax Therapeutics Reports Increased R&D Expenses Amid Clinical Trials

TIPRANKS
·
Nov 13, 2025

Tenax Therapeutics Q3 EPS $(0.40) Misses $(0.32) Estimate

Benzinga
·
Nov 13, 2025

Tenax Therapeutics posts Q3 net loss of $15.8 million

Reuters
·
Nov 13, 2025

BRIEF-Tenax Therapeutics Q3 Net Income USD -15.804 Million

Reuters
·
Nov 13, 2025

Tenax Therapeutics Inc expected to post a loss of 31 cents a share - Earnings Preview

Reuters
·
Nov 07, 2025

Tenax Therapeutics Hosts Virtual KOL Call on TNX-103 for PH-HFpEF

Reuters
·
Nov 06, 2025

Tenax Therapeutics to Present at Guggenheim Healthcare Innovation Conference

Reuters
·
Nov 03, 2025

Tenax Therapeutics Advances Phase 3 Study on Levosimendan for PH-HFpEF

TIPRANKS
·
Oct 28, 2025